Primary myelofibrosis (PMF) is a type of cloned myeloproliferative neoplasm stemming from haematopoietic stem cells, and tends to transform to acute myeloid leukaemia (AML) in approximately 10-20% of cases over a 10-year period. The transformation into AML has a poor prognosis, with a median overall survival of only 2.6 months in patients receiving supportive treatment. To date, treatment of AML transformation remains poor. The case of a 58-year-old female patient with AML transformed from PMF, who was treated with decitabine combined with all-trans retinoic acid, is reported. The patient had complete remission and a 17-month overall survival from initial diagnosis of transformed AML, with tolerated haematologic toxicity during the treatment period.
Introduction
Primary myelofibrosis (PMF) is one type of Philadelphia chromosome-negative myeloproliferative neoplasm, stemming from haematopoietic stem cells. Over a 10-year period, 10-20% of PMF cases would Department of Haematology, The First People's Hospital of Changzhou, Third Affiliated Hospital of Soochow University, Changzhou, China transform into acute myeloid leukaemia (PMF-tAML), 1 with subsequent rapid disease progression and a median survival time of only 2.6 months in patients receiving supportive treatment. 2 Despite this poor outcome risk, less than 10% of patients with PMF-tAML are indicated to receive allogeneic haematopoietic stem cell transplantation. 3 A few therapeutic agents, such as pegylated interferon-a-2a, 4 thalidomide, 5 azacitidine, 6 and decitabine 7 have recently shown positive effects in prolonging overall survival in patients with PMF-tAML.
Here, the case of a patient diagnosed with PMF-tAML treated with decitabine plus all-trans retinoic acid (RA), is presented. Treatment was deemed to be effective, with complete remission achieved after the fourth cycle of therapy. Disease-free survival reached approximately 5 months from the end of treatment, and overall survival reached 17 months from initial diagnosis of tAML. The treatment mechanism and side effects associated with decitabine in treating PMF-tAML are discussed, based on a review of relevant literature.
Case report
Relevant approval was obtained from the Ethics Committee of The First People's Hospital of Changzhou, Third Affiliated Hospital of Soochow University, Changzhou, China, and the patient, or legal proxy, provided written informed consent for publication of the case.
A 58-year-old Chinese female was admitted to the Department of Haematology, The First People's Hospital of Changzhou, Third Affiliated Hospital of Soochow University, on 11 May 2014, due to significantly increased white blood cell (WBC) count for the previous 7 years and weakness and leg pain for 1 month. The patient had a history of diabetes mellitus and had been regularly receiving metformin for glycaemic control. At a routine physical examination in 2007, the patient was found to have abnormally increased WBCs and splenomegaly, and a bone marrow smear revealed active proliferation and an increase in megakaryocytes. The patient then received a splenectomy at a community hospital and the immunohistochemistry showed active proliferation of the red pulp in the spleen. Following the splenectomy, the patient had been periodically re-examined at the community hospital. The WBC level had continued to rise to 50 Â 10 9 cells/l and examination of the presence of the breakpoint cluster region gene and the cellular abl (BCR/ABL) fusion gene was negative. The patient was prescribed hydroxyurea (1.5-6 g per day, according to WBC levels) and the WBC level was stabilised at 10-12 Â 10 9 cells/l. From 1 month prior to hospital admission in May 2014, the patient had developed noticeable dizziness, weakness and severe pain in both calves. At the outpatient clinic, routine blood test results showed a WBC count of 10.89 Â 10 9 cells/l, haemoglobin (Hb) at 86 g/l and platelet count of 55 Â 10 9 /l. Results from a peripheral blood smear revealed 7% primary blood cells. Attempts to perform bone marrow aspirations from the anterior superior iliac spine, posterior superior iliac spine and sternum were all unsuccessful due to dry tap.
At hospital admission, physical examinations showed a body temperature of 38.8 C and anaemic appearance, but no swollen superficial lymph nodes, sternal tenderness, hepatomegaly or limb oedema were observed. The routine blood test revealed a WBC count of 8.63 Â 10 9 cells/l, Hb level of 73 g/l and platelet count of 35 Â 10 9 /l. The peripheral blood smear showed 5% primary cells, 1% premyelocytes, and 20% myelocytes. Flow cytometry of peripheral blood, performed using the BD FACSCalibur TM equipment and associated reagents and antibodies (BD Biosciences, San Jose, CA, USA) according to the manufacturer's instructions, showed that blood cells were positive for CD13, CD22, CD33 and CD34. Cytogenetic analysis of peripheral blood revealed the following karyotype: 46, XX, t(7;20) (q21;q13)-11, add (14) (q32), þM [12] . Genetic analysis, performed using an Applied Biosystems TM 7500 Real-Time PCR System (ThermoFisher Scientific, Waltham, MA USA) according to the manufacturer's instructions, showed the blood samples to be BCR/ABL fusion genenegative, Janus kinase 2 (JAK2)-V617 gene mutation-positive, MPL protooncogene, thrombopoietin receptor (MPL) gene mutation-negative, calreticulin (CALR) gene mutation-negative, immunoglobulin heavy chain (IgH)-negative and T cell receptor (TCR) gene rearrangementnegative. Examination of liver function showed as following: albumin, 27 g/l; lactate dehydrogenase (LDH), 674 U/l; and fasting blood glucose, 7.24 mmol/l. An electrocardiogram showed sinus tachycardia and a change to part of the T wave. Chest X-ray showed increased lung markings. An ultrasound scan showed typical manifestations after splenectomy and gallstones. Posterior bone marrow biopsy revealed granulocyte hyperplasia with a majority of primary and immature granulocytes, significantly decreased megakaryocytes and fibrous tissue proliferation (Figure 1a and 1b). The diagnosis was considered to be PMF transforming into leukaemia, and considering all of the above examination results, a firm diagnosis of PMF-tAML was made.
Following hospital admission, the patient was intermittently infused with red blood cells and apheresis platelets. Following the second treatment cycle, an obvious improvement in routine blood test parameters was achieved. After the third treatment cycle, the routine blood test showed that WBC count, Hb level and platelet count were further improved and bone marrow aspirations were successfully obtained from the sternum. The bone marrow smear showed active proliferation of karyocytes with 58 megakaryocytes observed on the whole bone marrow smear slide, increased platelets and 4% primitive cells (Figure 1c ). Re-examination of blood samples for the presence of the JAK2-V617 gene mutation gave a negative result. The routine blood parameter results, including WBC count, Hb level, platelet count and neutrophil cycle, all returned to normal levels after the fourth treatment cycle (Figure 2a and 2b) . Thus, complete remission was achieved. The patient then stopped the decitabine plus all-trans RA therapy, after which, routine blood tests were performed every 2 weeks and showed that WBC count, Hb levels and platelets were all within normal ranges for approximately 5 months (data not shown). In April 2015, the patient developed anaemia and thrombocytopenia again, which indicated disease progression. The patient did not continue with targeted therapy and did not receive any further relevant examinations. The patient died in October 2015 following several months of supportive treatment. The curative effect of treatment with decitabine plus all-trans RA was satisfactory, with a disease-free survival duration of approximately 5 months from the end of treatment with decitabine plus alltrans RA, and an overall survival of 17 months from initial diagnosis of tAML.
Discussion
Acute myeloid leukaemia that has transformed from PMF is associated with a poor clinical outcome: Median overall survival is only 2.6 months in patients receiving supportive treatment, and only 3.9 months in patients receiving an introductive chemotherapy regimen including anthracyclines plus cytosine arabinoside. 2 Median overall survival in patients with PMF is 3-7 years and it takes approximately 10-15 years for PMF to progress to AML. 7 These data suggest that early detection of PMF may facilitate an improved prognosis.
In 2016, the World Health Organisation proposed a diagnosis standard for prefibrotic/early primary myelofibrosis (prePMF), involving change or abnormality in blood cell count, relevant gene mutations, increasing LDH levels, and splenomegaly. 8 Of particular note is the fact that splenomegaly in the early phase of disease is a possible sign of prePMF or PMF, and genetic analyses may help diagnose prePMF.
The JAK2/signal transducer and activator of transcription (STAT) signalling pathway plays an important role in cell proliferation, differentiation, apoptosis and immune regulation, 9 and many cases of PMF are found to bear a mutation in the JAK2 gene. 10 Protein-tyrosine phosphatase SHP-1 (encoded by the protein tyrosine phosphatase, non-receptor type 6 gene) negatively regulates the JAK2/STAT signalling pathway, and has been shown to be epigenetically inactivated by aberrant hypermethylation of its promotor, which is thought to contribute to the constitutive activation of JAK2/STAT signalling in patients with myeloproliferative neoplasms. Thus, demethylation therapy that targets SHP1 (which is involved in regulating the JAK2/STAT signalling pathway) may contribute to treatment for patients with myeloproliferative neoplasm. 11 Investigation of methylation using genome arrays has revealed that gene hypermethylation is a promotive factor for PMF transforming to AML. 12, 13 Thepot et al. 6 found that the overall response rate (ORR) in patients with myeloproliferative neoplasm transformed to AML, who were treated with azacytidine, was 38%, with a median overall survival of 8 months. Another study reported an ORR of 29% in patients with myeloproliferative neoplasm transformed to AML treated with decitabine, and a median overall survival of 10.5 months. 7 In patients with high-risk PMF treated with decitabine, the ORR was 82% and the median overall survival was 32 months. 7 These data suggest that demethylation drugs, including decitabine, appear to be superior to a regimen of anthracyclines plus cytosine arabinoside in prolonging the overall survival of patients with PMF-tAML.
All-trans RA is a drug that targets acute promyelocytic leukaemia (APL). It not only targets the retinoic acid receptor (RAR)a gene to induce differentiation of APL cells, but also targets the RARb gene to inhibit tumour cell proliferation and promote tumour cell apoptosis.
14 Numerous researchers have highlighted the synergistic effect of promoting tumour cell apoptosis and differentiation by combination therapy using all-trans RA and decitabine. [15] [16] [17] [18] Previous studies found that all-trans RA plus decitabine could induce the apoptosis and differentiation of leukemia cell lines K562, SHI-1 and U937 via upregulation of RARb gene expression. 15, 17, 18 In clinical practice, the ORR to treatment with alltrans RA plus decitabine in patients with myeloid leukaemia who cannot tolerate strong chemotherapy is 58.1%, with a median overall survival of 11 months. 19 In the present case, the diagnosis of PMF transforming into AML in addition to complex karyotypes, predicted a poor prognosis. Induction chemotherapy based on cytosine arabinoside has not been found to significantly prolong overall survival and may cause post-chemotherapy bone marrow depression due to toxicity of chemotherapeutic drugs. Thus, in the present case, decitabine plus all-trans RA was administered. After the fourth treatment cycle, complete remission was confirmed. Disease-free survival reached approximately 5 months from the end of treatment with decitabine plus all-trans RA, and the patient had a 17-month overall survival from initial diagnosis of tAML.
Decitabine for treating AML is administered in either 3-day or 5-day regimens. According to the prescribing information for decitabine, there are two recommended regimens for decitabine administration: option 1, decitabine is administered at a dose of 15 mg/m 2 by continuous intravenous infusion over 3 hours repeated every 8 hours for 3 days. The cycle is repeated every 6 weeks; or option 2, decitabine is administered at a dose of 20 mg/m 2 by continuous intravenous infusion over 1 hour repeated daily for 5 days. The cycle is repeated every 4 weeks. The 3-day regimen (45 mg/m 2 /day decitabine, 3 times per day for 3 days, 6 weeks for 1 cycle) has been less used due to its severe side effects. 20 In the 5-day regimen, decitabine is administered at 15 mg/m 2 /day, once a day for 5 days, 4 weeks for 1 cycle. Decitabine dosed at 15 mg/m 2 has been reported to increase the platelet count by promoting the release of platelets and the maturation of megakaryocytes. 21 Given that the platelet count of the present patient was low, the 5-day regimen of 15 mg/m 2 /day decitabine, once a day for 5 days, 4 weeks for 1 cycle, was chosen for treatment.
Chen et al. 22 /day all-trans RA (days 1-28) to successfully treat 31 cases of myeloid neoplasms not suitable for intensive chemotherapy, with an ORR of 58.1% and a 2-year survival rate of 26.6%. 15 The side effects were mainly tolerable haematologic toxicities. In the present case, the same regimen was used to treat a patient diagnosed with PMF-tAML. The side effects were manageable, avoiding the severe myelosuppression associated with chemotherapy based on cytosine arabinoside administration.
In summary, the case of a patient with PMF-tAML who was successfully treated with a regimen of 15 mg/m 2 /day decitabine (once daily for 5 days; 4 weeks for 1 cycle) plus all-trans RA, is reported. The case provides evidence and indications that a regimen of decitabine plus all-trans RA may be a safe and effective treatment alternative for PMF-tAML. This regimen may effectively prolong overall survival with minimal side effects and avoid severe myelosuppression following chemotherapy.
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